- page

Domain Therapeutics strengthens leadership team to spearhead global development and North American e...

Domain Therapeutics announces the European Patent Office decision to grant a patent for its propriet...

Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further ...

Domain Therapeutics announces nomination of first-in-class PAR2 NAM candidate, DT-9045, to unlock n...

Domain Therapeutics to present three posters at AACR 2023 annual meeting

Domain Therapeutics to Participate in Upcoming Investor and Industry Conferences

Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients...

Domain Therapeutics strengthens Scientific Advisory Board with appointment of immuno-oncology expert...